Your results for

Filter by

Filter by
Results

Filter by

Content type
Key content topics
Key audience
Top cancer treatments

Analysis of particle therapy registries based on a unified treatment policy for esophageal cancer.

16/06/2023
/ Publications
/
Toxicity

Based on data from a registry, clinical outcomes of 174 patients were analyzed in this study. With a median follow-up period 908 days, the 3-year OS rates for...

Proton beam therapy in rectal cancer: A systematic review and meta-analysis.

16/09/2021
/ Publications
/
IMRT
Dosimetry

This review article examined eight original studies with a total of 127 patients. There was significantly less irradiated small bowel with PBT compared to 3DCRT...

Hematologic Toxicity Comparison of Intensity Modulated Proton Therapy and Intensity Modulated Radiation Therapy in Anal Cancer Patients.

16/06/2022
/ Publications
/
IMRT
IMPT
Dosimetry

This study compared hematologic toxicity in 41 anal cancer patients treated with IMPT (n=14) or IMRT (n=27). This study found all pelvic bone marrow dose...

Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy.

16/03/2021
/ Publications
/
Toxicity

102 patients were treated with proton radiation after prostatectomy to the prostate bed or to prostate-bed and pelvic-node. With a median follow-up of 5.5 years...

A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity-Modulated Radiation Therapy in Early Stage Prostate Cancer Patients.

16/06/2021
/ Publications
/
Hypofractionation
Toxicity
IMRT

This multi-institutional study compared late toxicity profiles of a total of 1850 patients, including 1282 IMRT and 568 PBT. Overall toxicity rates were low...

Expand imaging capabilities of your system by adding Cone Beam CT

17/12/2020
/ User Meeting
/
Cone Beam CT - CBCT

During this event, you will learn from your peers how adding Cone Beam CT to your system will expand your imaging capabilities: Prof. Liang from UFHPTI will...

Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trial.

16/06/2023
/ Publications

Based on the PCG registry data, this is the largest study evaluating outcomes of 605 patients with localized high-risk prostate cancer (HRPC) treated with...

Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.

16/05/2023
/ Publications
/
Toxicity

This study reported outcomes of 23 patients with gynecologic malignancies treated with PBSPRT. 12 (52.2%) patients had uterine cancer, 10 (43.5%) cervical, and...

Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory lymphoma: A PTCOG and PCG Collaboration.

16/01/2021
/ Publications
/
Toxicity

Symptomatic pneumonitis, a subacute toxicity, has an incidence of 17% to 24% (≥grade 2) even with IMRT. A total of 85 patients with r/r lymphoma (66% HL, 34%...

Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.

16/06/2021
/ Publications

This study reviewed 56 mediastinal lymphoma patients treated with proton therapy and reported that nearly all treated patients fit the International Lymphoma...